UBS Initiates Coverage On Chemed with Buy Rating, Announces Price Target of $650

Benzinga Newsdesk www.benzinga.com Neutral 70.5%

Neg 0% Neu 70.5% Pos 0%

UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.

Comments

No comments yet. Be the first!